Please wait, while we are loading the content...
Please wait, while we are loading the content...
| Content Provider | World Health Organization (WHO)-Global Index Medicus |
|---|---|
| Author | Tran, Linda Zielinski, Angela Roach, Arpi H. Jende, Jennifer A. Householder, Ann Marie Cole, Emily E. Atway, Shuruq A. Amornyard, Melinda Accursi, Mallory L. Shieh, Suzanna W. Thompson, Erin E. |
| Description | Country affiliation: United States Author Affiliation: Tran L ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA linda.tran5@va.gov.); Zielinski A ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Roach AH ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Jende JA ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Householder AM ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Cole EE ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Atway SA ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Amornyard M ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Accursi ML ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Shieh SW ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.); Thompson EE ( Chalmers P. Wylie Veterans Affairs Ambulatory Care Center, Columbus, OH, USA.) |
| Abstract | OBJECTIVE: To review the oral and injectable pharmacologic treatment options for type 2 diabetes. DATA SOURCES: A literature search was conducted using PubMed electronic database for studies published in English between 1993 and September 2014. Search terms included diabetes mellitus, type 2 diabetes, and the individual name for each antidiabetic medication reviewed. In addition, manual searches were performed for cross-references from publications. Package inserts, United States Food and Drug Administration (FDA) Web site, Institute for Safe Medication Practices Web site, American Diabetes Association Web site and scientific session poster presentations, and individual drug company Web pages were also reviewed. STUDY SELECTION AND DATA EXTRACTION: This review focused on information elucidated over the past 10 years to assist prescribers in choosing optimal therapy based on individual patient characteristics. Studies leading to the approval of or raising safety concerns for the antidiabetic medications reviewed in this article were included. DATA SYNTHESIS: In the past 10 years, there have been 4 novel oral antidiabetic medication classes and 10 new injectable agents and insulin products approved by the FDA for the treatment of type 2 diabetes as well as new information regarding the safety and use of several older antidiabetic medication classes. The distinctions were reviewed for each individual agent, and a comparison was completed if there was more than one agent in a particular therapeutic class. Using current information available, select investigational agents in phase III trials or with a pending new drug application were highlighted. CONCLUSION: There are now 9 distinct oral pharmacologic classes and a variety of insulin and noninsulin injectable medications available for the treatment of type 2 diabetes. Metformin remains the first-line treatment option for most patients. When considering options for alternative or additional treatment, prescribers must weigh the benefits and risks using individual patient characteristics. |
| File Format | HTM / HTML |
| ISSN | 10600280 |
| Issue Number | 6 |
| Volume Number | 49 |
| e-ISSN | 15426270 |
| Journal | Annals of Pharmacotherapy |
| Language | English |
| Publisher | SAGE Publications |
| Publisher Date | 2015-06-01 |
| Publisher Place | United States |
| Access Restriction | One Nation One Subscription (ONOS) |
| Subject Keyword | Discipline Pharmaceutical Science Diabetes Mellitus, Type 2 Drug Therapy Hypoglycemic Agents Therapeutic Use Metformin Humans Administration & Dosage Insulin Journal Article Review |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) |
National Digital Library of India (NDLI) is a virtual repository of learning resources which is not just a repository with search/browse facilities but provides a host of services for the learner community. It is sponsored and mentored by Ministry of Education, Government of India, through its National Mission on Education through Information and Communication Technology (NMEICT). Filtered and federated searching is employed to facilitate focused searching so that learners can find the right resource with least effort and in minimum time. NDLI provides user group-specific services such as Examination Preparatory for School and College students and job aspirants. Services for Researchers and general learners are also provided. NDLI is designed to hold content of any language and provides interface support for 10 most widely used Indian languages. It is built to provide support for all academic levels including researchers and life-long learners, all disciplines, all popular forms of access devices and differently-abled learners. It is designed to enable people to learn and prepare from best practices from all over the world and to facilitate researchers to perform inter-linked exploration from multiple sources. It is developed, operated and maintained from Indian Institute of Technology Kharagpur.
Learn more about this project from here.
NDLI is a conglomeration of freely available or institutionally contributed or donated or publisher managed contents. Almost all these contents are hosted and accessed from respective sources. The responsibility for authenticity, relevance, completeness, accuracy, reliability and suitability of these contents rests with the respective organization and NDLI has no responsibility or liability for these. Every effort is made to keep the NDLI portal up and running smoothly unless there are some unavoidable technical issues.
Ministry of Education, through its National Mission on Education through Information and Communication Technology (NMEICT), has sponsored and funded the National Digital Library of India (NDLI) project.
| Sl. | Authority | Responsibilities | Communication Details |
|---|---|---|---|
| 1 | Ministry of Education (GoI), Department of Higher Education |
Sanctioning Authority | https://www.education.gov.in/ict-initiatives |
| 2 | Indian Institute of Technology Kharagpur | Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project | https://www.iitkgp.ac.in |
| 3 | National Digital Library of India Office, Indian Institute of Technology Kharagpur | The administrative and infrastructural headquarters of the project | Dr. B. Sutradhar bsutra@ndl.gov.in |
| 4 | Project PI / Joint PI | Principal Investigator and Joint Principal Investigators of the project |
Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon |
| 5 | Website/Portal (Helpdesk) | Queries regarding NDLI and its services | support@ndl.gov.in |
| 6 | Contents and Copyright Issues | Queries related to content curation and copyright issues | content@ndl.gov.in |
| 7 | National Digital Library of India Club (NDLI Club) | Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach | clubsupport@ndl.gov.in |
| 8 | Digital Preservation Centre (DPC) | Assistance with digitizing and archiving copyright-free printed books | dpc@ndl.gov.in |
| 9 | IDR Setup or Support | Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops | idr@ndl.gov.in |
|
Loading...
|